Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

Scroll down and select country
MEBO TMAU TESTING CURRENTLY SUSPENDED INDEFINITELY

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact info@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts

MEBO TMAU Videos

Petitions

TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

London TMAU meeting with Prof Liz Shephard
19th Oct 11am - 1pm
St Mary's Hospital
Praed St, Paddington
London W2 1NY
click to read more
more details : karen.james@meboresearch.org

MEBO Research Clinical Trials

Click here to read details of the MEBO Clinical Trials
NCT03582826 - Ongoing not recruiting
Microbial Basis of Systemic Malodor and PATM Conditions (PATM)
United States 2018 - ongoing

NCT02683876 - Completed
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
Canada and United States 2016 - ongoing

NCT03451994 - Completed
Exploratory Study of Volatile Organic Compounds in Alveolar Breath
United Kingdom and United States 2013 - ongoing

NCT02692495 - Completed
Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
United Kingdom 2009 - 2012

Monday, September 24, 2018

uBiome Expands Product Portfolio, Drug Discovery & Development

uBiome Announces $83 Million Series C Financing


uBiome Will Expand World’s Largest Human Microbiome Database 
and Advance Product Portfolio, 
Including Drug Discovery & Development
September 21, 2018

Considered to be "the leader in microbial genomics", uBiome announces that it has received $83 Million Series C Financing to expand its world's largest human microbiome database, advance product portfolio, drug discovery & development.

Proceeds of the financing will be used to:
  • Enhance and expand the Company’s product portfolio
  • Leverage insights gained by building largest microbiome database to expand into drug research and development using pre-existing patent assets and industry research collaborations, not data sales
  • Accelerate and expand commercialization of SmartGut, SmartJane, Explorer and other clinical tests under development, including companion diagnostics
  • Begin commercialization of biopharma molecules and live biotherapeutics based on mining of existing IP

uBiome has partnered with more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, University of California, San Francisco, the Massachusetts Institute of Technology, Oxford University, and the University of Sydney.

MEBO is currently participating in the uBiome's database expansion. It is our hope, though not a guarantee...that this clinical trial will ultimately lead to drug discovery & development.
With a uBiome Research Grant sponsoring MEBO's Clinical Trial, NCT02683876, "Microbial Basis of Systemic Malodor and PATM Conditions", MEBO is currently participating in the uBiome's database expansion. It is our hope, though not a guarantee, as stated in MEBO's Research Consent Form, that this clinical trial will ultimately lead to drug discovery & development.

The international MEBO community is most grateful to uBiome for the research grant it has awarded us for our Clinical Trial. We look forward to uBiome's expansion of its advanced product portfolio and drug discovery and development, which we hope will help our community arrive at proper diagnoses and targeted, personalized treatment protocols moving forward.

María


María de la Torre
Founder and Executive Director

A Public Charity
maria.delatorre@meboresearch.com
www.meboresearch.org
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)


SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.

get New Posts by EMAIL : Enter your email address :



A EURORDIS and NORD Member Organization

1 comments:

Anonymous said...

I have read that fecal transplant could help, but in the US it can't be done unless you have c-diff. Why, is there is a chance to help people is it limited to patients with c-diff. People are committing suicide over this malodor disorder and the FDA does not care I guess

Oct 13, 2018, 11:22:00 PM
Post a Comment